Accessibility Menu
Telix Pharmaceuticals logo

Telix Pharmaceuticals(OTC) TLPPF

Current Price$10.48
Market Cap$3.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+861%
5 Year+167%
1 Year-25%
1 Month+4%
Telix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 10.482026-07-24
Telix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.53%USD 11.092026-07-16
1 month+4.38%USD 10.042026-06-24
3 month+0.29%USD 10.452026-04-24
Year to date+35.47%USD 7.742025-12-31
1 year-24.84%USD 13.942025-07-24
3 year+45.15%USD 7.222023-07-25
5 year+167.35%USD 3.922021-07-23
Since inception+861.47%USD 1.092019-07-25

Telix Pharmaceuticals Financials at a Glance

Market Cap

$3.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.01B

Net Income (TTM)

A$39.06M

EPS (TTM)

-$0.02

P/E Ratio

-493.36

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$10.48

Volume

800

Open

$10.48

Previous Close

$10.48

Daily Range

$10.48 - $10.48

52-Week Range

$5.91 - $14.00

Estimated Earnings Date

Aug 20, 2026

TLPPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates in three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a strong emphasis on innovative cancer treatments.

Products and Services
  • TLX591: A lutetium-labeled radio antibody-drug conjugate for advanced prostate cancer
  • TLX250: An rADC targeting advanced metastatic kidney cancer
  • Illuccix and Gozellix: Radiopharmaceuticals for prostate cancer treatment
Growth Outlook
  • Recent quarterly revenue reached AUD 630.7 million, indicating strong market demand
  • Ongoing Phase 3 trials for TLX591 and TLX250 highlight significant development potential
  • Expansion into international markets enhances growth opportunities
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 2.1 billion reflects robust sales growth
  • Operating income margin improved to 1.58% in the latest quarter
  • Cash and cash equivalents stood at AUD 212.7 million, providing financial stability
Telix Pharmaceuticals Limited is positioned at the forefront of the biopharmaceutical industry, particularly in the oncology sector. The company's innovative approach to radiopharmaceuticals aims to address unmet medical needs in cancer treatment. With a diverse pipeline of products and a commitment to precision medicine, Telix is well-equipped to capitalize on the growing demand for targeted therapies. The recent financial performance underscores the company's potential for sustained growth, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Jul 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,184

CEO

Christian P. Behrenbruch, PhD, EMBA

Website

www.telixpharma.com

Headquarters

North Melbourne, VIC 3051, AU

TLPPF Financials

Key Financial Metrics (TTM)

Gross Margin

50.76%

Operating Margin

2.11%

Net Income Margin

-0.89%

Return on Equity

-1.72%

Return on Capital

2.08%

Return on Assets

-0.61%

Earnings Yield

-0.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

339.78M

Volume

800

Avg. Volume

3.53K

Financials (TTM)

Gross Profit

A$1.13B

Operating Income

A$107.90M

EBITDA

A$155.40M

Operating Cash Flow

A$10.18M

Capital Expenditure

-A$84.29M

Free Cash Flow

-A$68.64M

Cash & ST Invst.

A$212.66M

Total Debt

A$699.77M

Telix Pharmaceuticals Performance Analysis

Telix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 110,983,5751846.6%
20232023-12-31AUD 333,573,719200.6%
20242024-12-31AUD 516,602,59754.9%
20252025-12-31AUD 803,794,00055.6%
Telix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-32.9%
Q42024-12-31214.5%
Q22025-06-30-0.2%
Q42025-12-316.3%
Telix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.238.5%
20232023-12-31AUD 0.01N/A
20242024-12-31AUD 0.10791.6%
20252025-12-31AUD -0.02N/A
Telix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-44.8%
Q42024-12-31230.3%
Q22025-06-30-109.4%
Q42025-12-31-110.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$630.70M

+123.9%

Gross Profit

A$332.84M

+48.6%

Gross Margin

52.77%

N/A

Market Cap

$3.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.16M

N/A

Employees

1,120

N/A

Net Income

-A$7.37M

-137.7%

EBITDA

A$29.40M

+27.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$212.66M

+72.6%

Total Debt

A$699.77M

+3911.3%

Accounts Receivable

A$207.42M

+220.2%

Inventory

A$55.58M

+221.1%

Long Term Debt

A$671.87M

+4129.3%

Short Term Debt

A$27.95M

+1692.9%

Return on Assets

-0.61%

N/A

Return on Invested Capital

1.81%

N/A

Free Cash Flow

-A$94.47M

-3426.4%

Operating Cash Flow

-A$54.35M

-611.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAMRFCamurus AB
$58.51+0.00%
SNPHYSanten Pharmaceutical Co., Ltd.
$11.65+0.22%
ANSLFAnsell Limited
$21.64+0.00%
BVNKFBavarian Nordic A/S
$27.69+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NVDANvidia
$206.84-0.01%

Questions About TLPPF

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at $10.48 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between $5.91 and $14.00.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of A$467.11M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported A$141.87M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services